Healthcare provider profile · identity verified

Mark G Brauning, MD

Internal Medicine · YORKTOWN HEIGHTS, NY · NPI 1750312393

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	912	302
Amlodipine Besylate	Amlodipine Besylate	339	114
Rosuvastatin Calcium	Rosuvastatin Calcium	332	110
Levothyroxine Sodium	Levothyroxine Sodium	232	76
Losartan Potassium	Losartan Potassium	202	72
Metoprolol Succinate	Metoprolol Succinate	199	64
Omeprazole	Omeprazole	194	75
Zolpidem Tartrate	Zolpidem Tartrate	170	32
Metformin Hcl	Metformin Hcl	133	47
Escitalopram Oxalate	Escitalopram Oxalate	132	40
Pantoprazole Sodium	Pantoprazole Sodium	126	42
Lisinopril	Lisinopril	123	45
Tamsulosin Hcl	Tamsulosin Hcl	119	45
Trazodone Hcl	Trazodone Hcl	116	36
Eliquis	Apixaban	102	32
Famotidine	Famotidine	100	40
Furosemide	Furosemide	97	42
Finasteride	Finasteride	93	29
Spironolactone	Spironolactone	84	31
Gabapentin	Gabapentin	77	29
Hydrochlorothiazide	Hydrochlorothiazide	74	29
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	72	28
Duloxetine Hcl	Duloxetine Hcl	72	24
Allopurinol	Allopurinol	71	27
Prednisone	Prednisone	69	37
Albuterol Sulfate Hfa	Albuterol Sulfate	65	37
Simvastatin	Simvastatin	64	22
Synthroid	Levothyroxine Sodium	61	22
Valsartan	Valsartan	61	22
Carvedilol	Carvedilol	60	18
Alendronate Sodium	Alendronate Sodium	58	22
Chlorthalidone	Chlorthalidone	58	21
Meloxicam	Meloxicam	58	28
Montelukast Sodium	Montelukast Sodium	58	22
Bupropion Xl	Bupropion Hcl	57	20
Sertraline Hcl	Sertraline Hcl	57	18
Ramipril	Ramipril	55	17
Alprazolam	Alprazolam	53	26
Pravastatin Sodium	Pravastatin Sodium	53	22
Ezetimibe	Ezetimibe	51	19
Metformin Hcl Er	Metformin Hcl	51	18
Fluticasone Propionate	Fluticasone Propionate	50	28
Olmesartan Medoxomil	Olmesartan Medoxomil	50	17
Metoprolol Tartrate	Metoprolol Tartrate	49	15
Mirtazapine	Mirtazapine	49	21
Atenolol	Atenolol	45	13
Clopidogrel	Clopidogrel Bisulfate	44	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	43	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	41	13
Clonazepam	Clonazepam	40	suppressed
Jardiance	Empagliflozin	40	11
Triamcinolone Acetonide	Triamcinolone Acetonide	40	19
Xarelto	Rivaroxaban	39	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	38	11
Azithromycin	Azithromycin	35	33
Citalopram Hbr	Citalopram Hydrobromide	32	suppressed
Glipizide Er	Glipizide	32	12
Hydralazine Hcl	Hydralazine Hcl	32	suppressed
Tramadol Hcl	Tramadol Hcl	31	suppressed
Oxycodone Hcl	Oxycodone Hcl	30	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	26	suppressed
Azelastine Hcl	Azelastine Hcl	26	16
Buspirone Hcl	Buspirone Hcl	26	11
Benazepril Hcl	Benazepril Hcl	25	suppressed
Glipizide	Glipizide	24	11
Ibandronate Sodium	Ibandronate Sodium	24	suppressed
Labetalol Hcl	Labetalol Hcl	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Lorazepam	Lorazepam	23	12
Mounjaro	Tirzepatide	23	suppressed
Ozempic	Semaglutide	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	11
Fenofibrate	Fenofibrate Nanocrystallized	21	suppressed
Glimepiride	Glimepiride	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Torsemide	Torsemide	19	suppressed
Trulicity	Dulaglutide	19	suppressed
Ketoconazole	Ketoconazole	18	suppressed
Myrbetriq	Mirabegron	18	suppressed
Naproxen	Naproxen	18	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	suppressed
Topiramate	Topiramate	18	suppressed
Clotrimazole	Clotrimazole	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	14
Clonidine Hcl	Clonidine Hcl	16	suppressed
Diazepam	Diazepam	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	16	16
Enalapril Maleate	Enalapril Maleate	16	suppressed
Hydrocortisone	Hydrocortisone	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Potassium Chloride	Potassium Chloride	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	14	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Irbesartan	Irbesartan	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Pulmicort Flexhaler	Budesonide	12	suppressed
Advair Diskus	Fluticasone Propion/Salmeterol	11	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Emgality Pen	Galcanezumab-Gnlm	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Fenofibrate	Fenofibrate,micronized	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Nystatin	Nystatin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error